Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EBITDA over the past 16 years, most recently at $5.3 million for Q2 2025.

  • Quarterly results put EBITDA at $5.3 million for Q2 2025, up 147.88% from a year ago — trailing twelve months through May 2025 was -$17.2 million (down 181.17% YoY), and the annual figure for FY2025 was -$17.2 million, down 94.99%.
  • EBITDA for Q2 2025 was $5.3 million at Lifecore Biomedical, Inc. \De\, up from -$9.0 million in the prior quarter.
  • Over the last five years, EBITDA for LFCR hit a ceiling of $15.6 million in Q1 2024 and a floor of -$38.3 million in Q4 2021.
  • Median EBITDA over the past 5 years was -$7.8 million (2023), compared with a mean of -$7.5 million.
  • Biggest five-year swings in EBITDA: tumbled 1377.28% in 2021 and later skyrocketed 213.56% in 2023.
  • Lifecore Biomedical, Inc. \De\'s EBITDA stood at -$38.3 million in 2021, then skyrocketed by 67.28% to -$12.5 million in 2022, then skyrocketed by 213.56% to $14.2 million in 2023, then tumbled by 113.78% to -$2.0 million in 2024, then soared by 371.92% to $5.3 million in 2025.
  • The last three reported values for EBITDA were $5.3 million (Q2 2025), -$9.0 million (Q1 2025), and -$2.0 million (Q4 2024) per Business Quant data.